Barr Allegra approval
Executive Summary
Barr receives first ANDA approval for generic equivalent to Sanofi-Aventis'Allegra 60 mg capsules July 13. Barr maintains it is the first to file an ANDA for fexofenadine and is therefore entitled to a 180-day exclusivity period. Barr remains in litigation with Sanofi in New Jersey district court over five Allegra patents; the firm says the case may go to trial in early 2006. Barr was approved by FDA to market Allegra-D (fexofenadine/pseudoephedrine) generics in April, but has not yet launched the product (1"The Pink Sheet" April 18, 2005, In Brief)...